Martingale Asset Management L P Has $620,000 Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Martingale Asset Management L P grew its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 190.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,569 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,650 shares during the quarter. Martingale Asset Management L P’s holdings in Jazz Pharmaceuticals were worth $620,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Versant Capital Management Inc boosted its holdings in Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 269 shares during the period. Itau Unibanco Holding S.A. bought a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its position in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. GAMMA Investing LLC increased its stake in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 116 shares during the period. Finally, Gladius Capital Management LP acquired a new position in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $33,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,110 shares of company stock valued at $720,160. Insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on JAZZ shares. TD Cowen decreased their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Royal Bank of Canada lifted their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, October 23rd. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $175.33.

Jazz Pharmaceuticals Stock Down 0.0 %

Shares of NASDAQ JAZZ opened at $121.58 on Tuesday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The firm’s 50-day simple moving average is $115.13 and its 200 day simple moving average is $111.21. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market cap of $7.35 billion, a price-to-earnings ratio of 17.12, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.